Geron (NASDAQ: GERN ) managed to get imetelstat (branded Rytelo) approved despite giving investors quite a scare after the FDA's negative comments before the advisory committee meeting. That was in March. The approval came in June - for "low- to intermediate-1 risk myelodysplastic syndromes (MDS) with About the TPT service Thanks for reading. At the Total Pharma Tracker, we offer the following :- Projected American Shared Revenue Backlog $250 $213 $200 ing Balance (million $150 $106 $104 $101 $100 $50 $0 12 ...

Q2 2024 Earnings Call August 8, 2024 Welcome and Introduction JOHN SCARLETT, M.D. Chairman and Chief Executive Officer ANDREW J. GRETHLEIN, PH.D. EVP, Chief Operating Officer; Interim Commercial Lead FAYE FELLER, M.D. EVP, Chief Medical Officer MICHELLE ROBERTSON EVP, Chief Financial Officer geron 2 Forward-Looking Statements During the course of this presentation and question-and-answer session, there will be forward-looking statements regarding future events, performance, plans, expectations and other pro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 Large accelerated filer Non-accelerated filer ☒ ☐ Accelerated filer Smaller reporting company ☐ ☐ GERON CORPORATION (Exac ...

Geron Corporation (NASDAQ:GERN) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Dr. John Scarlett - Chairman, Chief Executive Officer Dr. Andrew Grethlein - Executive Vice President, Chief Operating Officer Dr. Faye Feller - Executive Vice President, Chief Medical Officer Michelle Robertson - Executive Vice President, Chief Financial Officer. Aron Feingold - Vice President of Investor Relations, Corporate Communication Conference Call Participants Tara Bancroft - TD Cowe ...

Geron (GERN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 9.09%. A quarter ago, it was expected that this drugmaker would post a loss of $0.10 per share when it actually produced a loss of $0.09, delivering a surprise of 10%. Over the last four quarters, the company has surpassed consensu ...

Exhibit 99.1 & geron Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights U.S. commercial launch of RYTELO™ (imetelstat) began in June 2024 for patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who are relapsed/refractory to or ineligible for etythropoiesisstimulating agents (ESAs), regardless of ring sideroblast (RS) status NCCN Guidelines® updated to include the use of RYTELO in both RS+ and RS- patients for second-line treatme ...

Geron Corporation (GERN) obtained FDA approval for pipeline candidate imetelstat for the treatment of adult patients with low to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks. Shares of the company rose 18% on Jun 7, on the news. The FDA approved imetelstat, a telomerase inhibitor, under the brand name Rytelo for the above-mentioned indication. Current treatment options for those failing ESA are limited to s ...

Shares of Geron (GERN 18.00%) finished the week ended June 7 about 32% higher. The market was reacting to news the company's investors had been waiting to hear for decades. Rytelo is a new treatment for an underserved population. That's generally a recipe for success in the biotechnology industry, but independent companies launching their first commercial product tend to miss expectations. Reasons to buy Geron Corp stock The FDA approved Rytelo for patients with low- to intermediate-risk myelodysplastic syn ...

Geron Today Geron $4.73 +0.84 (+21.59%) 52-Week Range $1.64 ▼ Price Target $6.10 Add to Watchlist The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation NASDAQ: GERN into the spotlight, sparking a surge in Geron's stock price and attracting heightened attention from investors seeking opportunities within the healthcare sector and biotech sector. This momentous achievement marks a turning point for Geron and underscores the company's commitment to developing innovative therapies for ...

Geron (NASDAQ:GERN) stock is heading higher on Friday after getting approval from the Food and Drug Administration (FDA) for RYTELO. Rami Komrokji, MD, an investigator in the RYTELO clinical trials, said the following about the approval. How This Affects GERN Stock GERN stock is up 18.4% as of Friday morning and is up 114.9% since the start of the year. We have all of the hottest stock market news traders need to know about on Friday. A few examples include what's happening with shares of Apple (NASDAQ:AAPL ...